Eli Lilly and Company (LLY)
| Market Cap | 709.71B |
| Revenue (ttm) | 40.86B |
| Net Income (ttm) | 8.37B |
| Shares Out | 900.43M |
| EPS (ttm) | 9.25 |
| PE Ratio | 85.22 |
| Forward PE | 35.58 |
| Dividend | $5.20 (0.66%) |
| Ex-Dividend Date | Nov 15, 2024 |
| Volume | 2,249,218 |
| Open | 788.12 |
| Previous Close | 789.32 |
| Day's Range | 780.30 - 794.83 |
| 52-Week Range | 561.65 - 972.53 |
| Beta | 0.43 |
| Analysts | Strong Buy |
| Price Target | 962.05 (+22.06%) |
| Earnings Date | Oct 30, 2024 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the comp... [Read more]
Financial Performance
In 2023, Eli Lilly's revenue was $34.12 billion, an increase of 19.56% compared to the previous year's $28.54 billion. Earnings were $5.24 billion, a decrease of -16.08%.
Financial StatementsAnalyst Forecast
According to 22 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price forecast is $962.05, which is an increase of 22.06% from the latest price.
News
Calls of the Day: Martin Marietta, Datadog, Bristol-Myers, Eli Lilly and Disney
The Investment Committee debate the latest Calls of the Day.
Where to invest in GLP-1 stocks
Salveen Richter, Goldman Sachs lead U.S. biotech analyst, joins 'Squawk on the Street' to discuss Amgen's mid-stage trial results for its experimental obesity drug, why she remains bullish on the comp...
Millions more Americans might get access to GLP-1 drugs
A new proposal by the Biden administration would see obesity drugs covered under Medicare and Medicaid. Transcript: Conway Gittens: The Dow and the S&P 500 closed at fresh record highs on Tuesday as i...
Eli Lilly, Novo Nordisk Stocks Gain as Biden Moves to Expand Coverage of Weight-Loss Drugs
Eli Lilly (LLY) and Novo Nordisk (NVO) shares rose Tuesday after the Biden administration proposed expanding coverage of the companies' popular weight-loss drugs in government-backed healthcare plans ...
Biden administration plans to expand coverage of GLP-1 drugs for Americans with Medicare & Medicaid
CNBC's Bertha Coombs joins 'Squawk on the Street' to report on Biden's administration plan to expand coverage of GLP-1 drugs for Americans with Medicare and Medicaid.
Biden Proposes Medicare, Medicaid Access For Popular Weight-Loss Drugs
The Biden-Harris Administration has proposed expanding Medicare and Medicaid coverage for anti-obesity medications, aiming to address the high costs that have drawn criticism. In the U.S., Novo Nordis...
Mizuho's Jared Holz on what Trump's FDA pick means for biotech innovation
Mizuho's Jared Holz joins 'Fast Money' to talk what's next for biopharma space after president-elect Trump names his pick for FDA head.
Thankful Investors - Last 5 Years
We're highlighting the 25 best-performing stocks in the S&P 1500 on a total return basis over the last five years. At the top of the list, above even Nvidia, is Alpha Metallurgical, which mines and pr...
5 Best CEFs This Month For 8.5% Yield (November 2024)
For income investors, closed-end funds remain an attractive investment class that covers various asset classes and promises high distributions and reasonable total returns. Closed-end funds, or CEFs, ...
Eli Lilly: Steep Pullback, Still Compelling Here
LLY's recent sell-off has been unwarranted indeed, since the lowered FY2024 guidance is attributed to the complexities of inventory management and non-cash/ one-time IPR&D charges. Even so, the pullba...
Potential $5,000 Monthly Income: 10 Investments To Buy And Hold For Next 10 Years
We present a highly diversified yet simple portfolio of 10 positions, with 9 funds and one individual MLP stock. The portfolio has been designed for retirees and investors planning for retirement, wit...
Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs
Eli Lilly and Co. LLY has seen better days. The stock is up 26.04% for the last year but has struggled recently, falling 17.57% over the last month.
China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug
Eli Lilly and Hong Kong-listed Laekna will collaborate to develop an experimental obesity drug that aims to help patients lose weight while preserving muscle, the biotech said on Wednesday.
Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obesity
LOS ANGELES--(BUSINESS WIRE)-- #ActRII--Laekna, Inc. (2105.HK) (“Laekna”), a global biotech company focused on novel drug development for metabolic and cancer diseases, is pleased to announce a clinic...
Verge Genomics Announces Milestones in Collaboration with Lilly to Discover and Develop Novel Treatments for ALS
— Lilly to Develop Two Targets Identified and Validated Using Verge Genomics' AI-Enabled, All-in-Human CONVERGE® Platform
Lilly announces changes on board of directors
INDIANAPOLIS , Nov. 19, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it has elected Jon Moeller as a new member of its board of directors, effective Dec. 1, 2024. In add...
Healthy Returns: Eli Lilly's cholesterol pill impresses in mid-stage trial
Eli Lilly's cholesterol pill impressed in a mid-stage trial. Meanwhile, Dexcom invested $75 million in Oura.
RFK Jr.'s HHS nomination sparks concern over pharma stocks
President-elect Trump's decision to nominate Robert F. Kennedy Jr. as the Secretary of Health and Human Services (HHS) has sparked concerns, particularly about his skepticism toward the pharmaceutical...
Lilly pill cuts genetic form of cholesterol nearly 86% in study
The highest dose of an experimental pill developed by Eli Lilly dramatically lowered an inherited form of high cholesterol in a mid-stage trial, according to data presented at a medical meeting on Mon...
Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose
Muvalaplin, an oral, once-daily treatment that inhibits lipoprotein(a) formation via a novel mechanism, achieved positive results in a 12-week Phase 2 study These data were published in the Journal of...
Medicaid dominates coverage of Novo, Lilly weight-loss drugs
U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the reimbursement available from private employers and insurers, according to an ana...
Incyclix Bio Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate INX-315 in Combination with Verzenio® (abemaciclib) and Fulvestrant in HR+/HER2- Breast Cancer
INX-315, a potential best-in-class CDK2 inhibitor, to be evaluated in combination with Verzenio® (abemaciclib) and fulvestrant
Medicaid fuels US coverage of Novo, Lilly weight-loss drugs
U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the reimbursement available from private employers and insurers, according to an ana...
Eli Lilly and Novo Want to Shake off Ozempic Copycats. Are They Ready To Meet Demand?
The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it's unclear whether they can ramp up production enough.
Lilly's tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity
In a first-of-its-kind study, tirzepatide also alleviated heart failure symptoms and physical limitations Patients on tirzepatide experienced improved exercise capacity, greater weight loss and reduce...